Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) has been given a $6.00 price target by analysts at Maxim Group in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 90.48% from the company’s current price.
Several other research firms have also weighed in on IPCI. Zacks Investment Research upgraded shares of Intellipharmaceutics International from a “sell” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday, October 18th. Brean Capital initiated coverage on shares of Intellipharmaceutics International in a report on Monday, October 3rd. They issued a “buy” rating and a $8.00 target price on the stock.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded up 5.00% during trading on Friday, reaching $3.15. 1,180,890 shares of the company traded hands. The company’s market capitalization is $91.24 million. Intellipharmaceutics International has a 52 week low of $1.41 and a 52 week high of $3.35. The firm’s 50 day moving average price is $2.85 and its 200-day moving average price is $2.03.
A hedge fund recently raised its stake in Intellipharmaceutics International stock. Atria Investments LLC boosted its stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 12.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,895 shares of the company’s stock after buying an additional 8,168 shares during the period. Atria Investments LLC owned about 0.26% of Intellipharmaceutics International worth $159,000 at the end of the most recent quarter. 1.43% of the stock is owned by institutional investors.
About Intellipharmaceutics International